{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T11:45:40Z","timestamp":1767181540626,"version":"build-2238731810"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T00:00:00Z","timestamp":1479427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI13\/00155"],"award-info":[{"award-number":["PI13\/00155"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"AGAUR","doi-asserted-by":"crossref","award":["2014-SGR-605"],"award-info":[{"award-number":["2014-SGR-605"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0166631","type":"journal-article","created":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T13:42:15Z","timestamp":1479476535000},"page":"e0166631","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon"],"prefix":"10.1371","volume":"11","author":[{"given":"Martina","family":"Gambato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noelia","family":"Caro-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Ca\u00f1ete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"Mari\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabela","family":"Lens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mart\u00edn","family":"Bonacci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concepci\u00f3","family":"Bartres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9-Mar\u00eda","family":"S\u00e1nchez-Tapias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"Carri\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Forns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manel","family":"Juan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sof\u00eda","family":"P\u00e9rez-del-Pulgar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6533-1586","authenticated-orcid":true,"given":"Mar\u00eda-Carlota","family":"Londo\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,11,18]]},"reference":[{"issue":"13","key":"ref1","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"BR Bacon","year":"2011","journal-title":"N Engl J Med"},{"issue":"25","key":"ref2","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"S Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"ref3","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"KE Sherman","year":"2011","journal-title":"N Engl J Med"},{"issue":"13","key":"ref4","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"F Poordad","year":"2011","journal-title":"N Engl J Med"},{"issue":"25","key":"ref5","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"IM Jacobson","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/liv.12656","article-title":"Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis","volume":"35","author":"JL Calleja","year":"2015","journal-title":"Liver Int"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2014.03.051","article-title":"Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis","volume":"147","author":"C Hezode","year":"2014","journal-title":"Gastroenterology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0168-8278(13)60067-7","article-title":"Safety of triple therapy with telaprevir or boceprevir in hepatitis C patients with advanced disease- predictive factors for sepsis","volume":"58","author":"K Rutter","year":"2013","journal-title":"Abstract. Journal of Hepatol"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jhep.2014.09.025","article-title":"The Addition of a Protease Inhibitor Increases the Risk of Infections in Patients with Hepatitis C-Related Cirrhosis","volume":"62","author":"MC Londono","year":"2014","journal-title":"J Hepatol"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/lt.24366","article-title":"Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network","volume":"22","author":"RS Brown Jr.","year":"2016","journal-title":"Liver Transpl"},{"issue":"6","key":"ref11","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jhep.2014.01.024","article-title":"Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013","volume":"60","author":"R Jalan","year":"2014","journal-title":"J Hepatol"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1538-7836.2007.02865.x","article-title":"Platelets, neutrophils, and neutrophil extracellular traps (NETs) in sepsis","volume":"6","author":"AC Ma","year":"2008","journal-title":"Journal of thrombosis and haemostasis: JTH"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000296507","article-title":"Monocytes and macrophages regulate immunity through dynamic networks of survival and cell death","volume":"2","author":"A Parihar","year":"2010","journal-title":"Journal of innate immunity"},{"issue":"11","key":"ref14","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1128\/CVI.00130-07","article-title":"Direct effect of human immunodeficiency virus protease inhibitors on neutrophil function and apoptosis via calpain inhibition","volume":"14","author":"N Hadad","year":"2007","journal-title":"Clin Vaccine Immunol"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"e0150299","DOI":"10.1371\/journal.pone.0150299","article-title":"Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes","volume":"11","author":"W Spindelboeck","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2008.11.015","article-title":"Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study","volume":"50","author":"JA Carrion","year":"2009","journal-title":"J Hepatol"},{"issue":"5","key":"ref17","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/hep.25976","article-title":"A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis c after liver transplantation","volume":"57","author":"GT Everson","year":"2013","journal-title":"Hepatology"},{"issue":"5","key":"ref18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1358\/mf.2005.27.5.908646","article-title":"Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon-alpha2a plus ribavirin in chronic hepatitis C infection","volume":"27","author":"A Juarez-Navarro","year":"2005","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"9","key":"ref19","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/jvh.12197","article-title":"Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha and ribavirin","volume":"21","author":"A Striki","year":"2014","journal-title":"J Viral Hepat"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/hep.23842","article-title":"Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C","volume":"52","author":"R Roomer","year":"2010","journal-title":"Hepatology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1749-6632.2009.04623.x","article-title":"Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis","volume":"1173","author":"A Giorgini","year":"2009","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"ref22","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1089\/vim.2011.0078","article-title":"The influence of treatment with pegylated interferon-alfa and ribavirin on neutrophil function and death in patients with HIV\/HCV coinfection","volume":"25","author":"E Jablonowska","year":"2012","journal-title":"Viral Immunol"},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3109\/08923979609052752","article-title":"Effects of interferon-alpha treatment on neutrophil oxidative metabolism, lymphocyte proliferation and monocyte HLA class I antigen expression in patients with chronic hepatitis C","volume":"18","author":"G Piazzolla","year":"1996","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"10","key":"ref24","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/infdis\/jit801","article-title":"Monocyte activation by interferon alpha is associated with failure to achieve a sustained virologic response after treatment for hepatitis C virus infection","volume":"209","author":"DJ Hartigan-O'Connor","year":"2012","journal-title":"J Infect Dis"},{"issue":"8","key":"ref25","doi-asserted-by":"crossref","first-page":"e105665","DOI":"10.1371\/journal.pone.0105665","article-title":"The dynamic relationship between innate immune biomarkers and interferon-based treatment effects and outcome in hepatitis C virus infection is altered by telaprevir","volume":"9","author":"DF Malone","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-3083.2007.02028.x","article-title":"A novel modification of a flow cytometric assay of phosphorylated STAT1 in whole blood monocytes for immunomonitoring of patients on IFN alpha regimen","volume":"67","author":"J Vakkila","year":"2008","journal-title":"Scand J Immunol"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0170913","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T00:00:00Z","timestamp":1484870400000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0166631","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T14:03:22Z","timestamp":1718892202000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0166631"}},"subtitle":[],"editor":[{"given":"Golo","family":"Ahlenstiel","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,11,18]]},"references-count":26,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0166631","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,18]]}}}